Daniel Peeper is professor in Functional Oncogenomics heading the Department of Molecular Oncology & Immunology and chairing the Research Faculty Council Board at the Netherlands Cancer Institute (NKI), where he also set up and chaired the Translational Research Board. He has received several awards, including a KWF Queen Wilhelmina Award and a Society for Melanoma Research (SMR) Outstanding Researcher Award. He is an elected Member of Oncode (a funded network of selected cancer scientists in the Netherlands), EMBO and Academia Europaea and serves on several Boards, including that of the European Association for Cancer Research. His laboratory discovered the physiologic relevance and mechanism of Oncogene-Induced cellular Senescence as a tumor-suppressing mechanism in humans. More recently, his team has been focusing on translational cancer research, using function-based genetic screens for drug target identification and unraveling mechanisms mediating resistance, both for tumor and immune cell therapies. Several potential new tumor and immune cell drug targets have been identified and are being studied in preclinical models. His group also dissected the mechanism of cancer drug addiction and provided PoC of how this vulnerability may be used clinically, and developed a new rational concept for combinatorial targeting of intratumor heterogeneity. Most recently, his lab discovered that lowering the TNF threshold sensitizes tumors to T cell attack and immunotherapy.
« Go Back